Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT00842335 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors

Start date: February 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study, the first clinical trial of JI-101, is to determine the maximum tolerated dose of JI-101 when given orally to patients with solid tumors. Safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of the drug on tumor metabolism will also be studied. JI-101 is an inhibitor of new blood vessel growth that may provide benefit to patients with solid tumors that have failed standard therapeutic regimens.

NCT ID: NCT00831896 Completed - Clinical trials for Advanced Solid Tumors

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Start date: March 2009
Phase: Phase 1
Study type: Interventional

This study is a multicenter, open-label, dose escalation, phase 1 study of TAK 701 in adult patients with advanced nonhematologic malignancies. This study will be the first to administer TAK 701 to humans. The primary purpose of this study is to determine the safety profile, tolerability, and pharmacokinetics profile of TAK-701.

NCT ID: NCT00827177 Completed - Clinical trials for Advanced Solid Tumors

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Start date: September 2009
Phase: Phase 1
Study type: Interventional

This is an open-label, dose-escalation study of ARQ 197 administered orally in combination with sorafenib.

NCT ID: NCT00813384 Completed - Cancer Clinical Trials

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

Start date: December 2008
Phase: Phase 1
Study type: Interventional

First in human, open-label, sequential dose escalation and expansion study of AMG 208 in subjects with advanced solid tumors.

NCT ID: NCT00794781 Completed - Clinical trials for Advanced Solid Tumors

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

Start date: June 22, 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of E6201 in subjects with advanced solid tumors.

NCT ID: NCT00793975 Completed - Clinical trials for Advanced Solid Tumors

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

Start date: January 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.

NCT ID: NCT00793897 Completed - Clinical trials for Advanced Solid Tumors

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Start date: April 2009
Phase: Phase 1
Study type: Interventional

A Phase I dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in combination with chemotherapy drugs, paclitaxel and carboplatin, in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 in combination with paclitaxel and carboplatin for Phase 2 studies

NCT ID: NCT00792558 Withdrawn - Clinical trials for Advanced Solid Tumors

Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers

Start date: January 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find the maximum tolerated dose of BMS-817378 in subjects with advanced cancers

NCT ID: NCT00788099 Completed - Clinical trials for Advanced Solid Tumors

Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas

Start date: December 2008
Phase: Phase 1
Study type: Interventional

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination with Sorafenib or Gemcitabine in Patients with Advanced Solid Tumors or Lymphomas to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of plitidepsin in combination with sorafenib or gemcitabine in patients with advanced solid tumors or lymphomas.

NCT ID: NCT00785941 Completed - Clinical trials for Advanced Solid Tumors

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Start date: April 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if IMC-A12 is safe for patients, and also to determine the best dose of IMC-A12 to give to patients.